Press Release

FierceBiotech Names Revolution Medicines as a “Fierce 15” Biotech Company of 2015

September 30, 2015

Redwood City, CA – September 30, 2015 – REVOLUTION Medicines, Inc., a company focused on the discovery and development of innovative drugs derived from natural compounds, today announced that it has been named by FierceBiotech as one of 2015’s Fierce 15 biotechnology companies, recognizing it as one of the most promising private biotechnology companies in the industry.

Founded by Martin D. Burke, M.D., Ph.D., REVOLUTION Medicines announced its launch by Third Rock Ventures in February 2015 with a $45 million Series A financing. The company’s innovative approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures.

“At REVOLUTION Medicines, we are committed to transforming drug discovery with a product engine that empowers us to redesign nature’s diverse, biologically rich and complex products into powerful medicines for patients with serious diseases,” said Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer of REVOLUTION Medicines. “Since the relatively recent launch of REVOLUTION Medicines, we’ve made strong progress with two high-impact scientific publications by our academic founder, exciting progress in building our product engine and pipeline, as well as several key leadership and board appointments. It is truly an honor that our company’s innovative approach and team are validated by this selection as a member of the select ‘Fierce 15’ class of 2015.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s thirteenth annual Fierce 15 selection. A complete list of “Fierce 15” companies can be found online at

An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at


Media Contact:
Katie Engleman
Pure Communications, Inc.


The mission of REVOLUTION Medicines is redesigning evolution’s products to treat serious diseases. The company discovers and develops new drugs by reconfiguring natural substances that are inherently rich with biological function as a result of natural selection. REVOLUTION Medicines’ innovative product engine is based on the REVEAL™ platform, which uses evolution’s lessons to inform selection of chemical scaffolds, and the REVBLOCKS™ technology, a rapid, standardized and transformative synthesis process for assembling simple chemical “building blocks” into refined natural product-like structures with optimized pharmacologic and pharmaceutical properties. The company’s first leads are innovative small molecules that exploit and improve upon the properties of amphotericin B, a powerful, broad-spectrum antifungal compound found in nature that has avoided generating significant drug resistance in 50 years of clinical use. Headquartered in Redwood City, Calif. at the intersection of Silicon Valley and the birthplace of biotechnology, REVOLUTION Medicines is a private company financed by top-tier investor Third Rock Ventures. For more information, please visit